Trial · NCT04410328
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Covid (Coronavirus Disease-19) Ordinal Scale | Participants Receiving Dipyridamole and Aspirin | 2.3 | Standard Deviation 1.8 | score on a scale | |
| Covid (Coronavirus Disease-19) Ordinal Scale | Participants Receiving Standard of Care | 2.1 | Standard Deviation 2.0 | score on a scale | |
| Mortality | Participants Receiving Dipyridamole and Aspirin | 2 | Participants | ||
| Mortality | Participants Receiving Standard of Care | 2 | Participants | ||
| Mortality | Participants Receiving Dipyridamole and Aspirin | 3 | Participants | ||
| Mortality | Participants Receiving Standard of Care | 5 | Participants | ||
| Inflammatory Marker Between Baseline and 7 Days | Participants Receiving Dipyridamole and Aspirin | -197.5 | Inter-Quartile Range -2425.0 to 366.0 | ng/mL | |
| Inflammatory Marker Between Baseline and 7 Days | Participants Receiving Standard of Care | 114 | Inter-Quartile Range -1408.0 to 240.0 | ng/mL | |
| COVID Ordinal Scale | Participants Receiving Dipyridamole and Aspirin | 3 | Inter-Quartile Range 2 to 4 | scores on a scale | |
| COVID Ordinal Scale | Participants Receiving Standard of Care | 3 | Inter-Quartile Range 2 to 3 | scores on a scale | |
| Number of Participants Not Requiring Supplemental Oxygen | Participants Receiving Dipyridamole and Aspirin | 45 | Participants | ||
| Number of Participants Not Requiring Supplemental Oxygen | Participants Receiving Standard of Care | 43 | Participants | ||
| Invasive-ventilator | Participants Receiving Dipyridamole and Aspirin | 4 | Participants | ||
| Invasive-ventilator | Participants Receiving Standard of Care | 5 | Participants | ||
| ICU Stay | Participants Receiving Dipyridamole and Aspirin | 5 | Participants | ||
| ICU Stay | Participants Receiving Standard of Care | 7 | Participants | ||
| Inflammatory Marker | Participants Receiving Dipyridamole and Aspirin | 652.5 | Inter-Quartile Range 312 to 1752 | ug/L | |
| Inflammatory Marker | Participants Receiving Standard of Care | 381 | Inter-Quartile Range 115 to 521 | ug/L | |
| Inflammatory Marker | Participants Receiving Dipyridamole and Aspirin | 92 | Inter-Quartile Range 83 to 101 | ug/L | |
| Inflammatory Marker | Participants Receiving Standard of Care | 165 | Inter-Quartile Range 85 to 262 | ug/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04410328/results